Evidence map›Paper›PMID 40991662›Full record

ArticlePLoS biology2025

XDH-1 inactivation causes xanthine stone formation in Caenorhabditis elegans which is inhibited by SULP-4-mediated anion exchange in the excretory cell.

Jennifer Snoozy, Sushila Bhattacharya, Brandon Johnson, Robin R Fettig, Ashley Van Asma, Chloe Brede, Sophia G Miller, Martina Ralle, Kurt Warnhoff

Abstract read
In one paragraph

Article in PLoS biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Jennifer SnoozyPediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, South Dakota, United States of America.
Sushila BhattacharyaPediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, South Dakota, United States of America.
Brandon JohnsonPediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, South Dakota, United States of America.
Robin R FettigPediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, South Dakota, United States of America.
Ashley Van AsmaPediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, South Dakota, United States of America.
Chloe BredePediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, South Dakota, United States of America.
Sophia G MillerDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, United States of America.
Martina RalleDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, United States of America.
Kurt WarnhoffPediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, South Dakota, United States of America.ORCID 0000-0002-9503-0557

Funding

Enhancing and expanding the CGC Strain CollectionP40OD010440 · OD · UNIVERSITY OF MINNESOTA · PI Ann E. Rougvie · 2012 to 2026
$7.5M
Genetic analyses of molybdenum cofactor biologyR35GM146871 · NIGMS · SANFORD RESEARCH/USD · PI Kurt Warnhoff · 2022 to 2026
$2.1M
The Pediatric Biomedical Research ProgramR25HD097633 · NICHD · SANFORD RESEARCH/USD · PI LEE, LANCE, WEIMER, JILL M · 2019 to 2023
$527k
Inductively Coupled Plasma Mass Spectrometer for High Sensitivity Elemental AnalysisS10OD028492 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI RALLE, MARTINA · 2021 to 2021
$336k
NICHD NIH HHS R25 HD097633NIGMS NIH HHS R35 GM146871NIH HHS P40 OD010440NIH HHS S10 OD028492
6 · The paper itself

Abstract

Xanthine dehydrogenase (XDH) is a molybdenum cofactor (Moco) requiring enzyme that catabolizes hypoxanthine into xanthine and xanthine into uric acid, the final steps in purine catabolism. Human patients with mutations in XDH develop xanthinuria which can lead to xanthine stones in the kidney, recurrent urinary tract infections, and renal failure. Currently, there are no therapies for treating human XDH deficiency. Thus, understanding mechanisms that maintain purine homeostasis is an important goal of human health. Here, we used the nematode Caenorhabditis elegans to model human XDH deficiency using two clinically relevant paradigms: Moco deficiency or loss-of-function mutations in xdh-1, the C. elegans ortholog of XDH. Both Moco deficiency and xdh-1 loss of function caused the formation of autofluorescent xanthine stones in C. elegans. Surprisingly, only 2% of xdh-1 null mutant C. elegans developed a xanthine stone, suggesting additional pathways may regulate this process. To uncover such pathways, we performed a forward genetic screen for mutations that enhance the penetrance of xanthine stone formation in xdh-1 null mutant C. elegans. We isolated multiple loss-of-function mutations in the gene sulp-4 which encodes a sulfate permease homologous to human SLC26 anion exchange proteins. We demonstrated that SULP-4 acts cell-nonautonomously in the excretory cell to limit xanthine stone accumulation. Interestingly, sulp-4 mutant phenotypes were suppressed by mutations in genes that encode for cystathionase (cth-2) or cysteine dioxygenase (cdo-1), members of the sulfur amino acid catabolism pathway required for production of sulfate, a substrate of SULP-4. We propose that sulfate accumulation caused by sulp-4 loss of function promotes xanthine stone accumulation. We speculate that sulfate accumulation causes osmotic imbalance, creating conditions in the intestinal lumen that favor xanthine stone accumulation. Supporting this model, a mutation in osm-8 that constitutively activates the osmotic stress response also promoted xanthine stone accumulation in an xdh-1 mutant background. Thus, our work establishes a C. elegans model for human XDH deficiency and identifies the sulfate permease sulp-4 as a critical player controlling xanthine stone accumulation.

Indexed as

Caenorhabditis elegansCaenorhabditis elegans ProteinsXanthineXanthine DehydrogenaseAnimalsDisease Models, AnimalHumansMutationUric AcidCaenorhabditis elegans ProteinsUric AcidXanthineXanthine Dehydrogenase

Identifiers

PMID40991662
PMCPMC12479013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.